Galapagos Selected For AEX Index
The AEX represents the 25 largest companies traded on Euronext Amsterdam, subject to meeting Euronext Index Family criteria and review.
"We are proud that 11 years after our initial public listing on Euronext, Galapagos is included in the prestigious AEX Index. This reflects the evolution of Galapagos from a pioneering target discovery company to an integrated biopharmaceutical powerhouse," says Onno van de Stolpe, CEO and Founder.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our maturing pipeline comprises Phase 2, Phase 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contacts
| Investors: | Media: |
| Elizabeth Goodwin | Evelyn Fox |
|
VP IR & Corporate Communications +1 781 460 1784 |
Director Communications +31 6 53 591 999 communications@glpg.com |
|
Paul van der Horst Director IR & Business Development +31 6 53 725 199 |
|
| ir@glpg.com |